

DEAV2001/0073 US NP


PATENT

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A compound of formula I:



wherein

A is a nitrogen atom;

R1 and R3 are independently selected from the group consisting of

hydrogen,

halogen,

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen,

-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen,

-C(O)-O-R<sub>4</sub>,

-CN,

-N(R<sub>5</sub>)-(R<sub>6</sub>),

-OH,

-S-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-S(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and

-S(O)<sub>2</sub>-R<sub>7</sub>, and

DEAV2001/0073 US NP

PATENT

R2 is selected from the group consisting of

hydrogen,  
halogen,  
-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-C(O)-O-R<sub>4</sub>,  
-CN,  
-N(R<sub>5</sub>)-(R<sub>6</sub>),  
-OH,  
-S-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-S(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and

-S(O)<sub>2</sub>-R<sub>7</sub>; or R<sub>1</sub> and R<sub>2</sub>, taken together with the two carbon atoms of ring1 to which R<sub>1</sub> and R<sub>2</sub> are attached, form a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms which are independently oxygen, nitrogen and sulfur while R<sub>3</sub> is as defined above; or R<sub>2</sub> and R<sub>3</sub>, taken together with the two carbon atoms of ring1 to which R<sub>2</sub> and R<sub>3</sub> are attached, form a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms which are independently oxygen, nitrogen and sulfur while R<sub>1</sub> is not part of a ring and is as defined above;

R<sub>1</sub>' and R<sub>3</sub>' are independently selected from the group consisting of

hydrogen,  
halogen,  
-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen,  
-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen,  
-C(O)-O-R<sub>4</sub>,  
-CN,  
-N(R<sub>5</sub>)-(R<sub>6</sub>),

DEAV2001/0073 US NP

PATENT

-OH,  
-S-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-S(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and  
-S(O)<sub>2</sub>-R<sub>7</sub>, and

R<sub>2</sub>' is selected from the group consisting of

hydrogen,  
halogen,  
-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-C(O)-O-R<sub>4</sub>,  
-CN,  
-N(R<sub>5</sub>)-(R<sub>6</sub>),  
-OH,  
-S-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-S(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and

-S(O)<sub>2</sub>-R<sub>7</sub>; or R<sub>1</sub>' and R<sub>2</sub>', taken together with the two carbon atoms of ring<sub>2</sub> to which R<sub>1</sub>' and R<sub>2</sub>' are attached, form a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms which are independently oxygen, nitrogen and sulfur while R<sub>3</sub>' is as defined above; or R<sub>2</sub>' and R<sub>3</sub>', taken together with the two carbon atoms of ring<sub>2</sub> to which R<sub>2</sub>' and R<sub>3</sub>' are attached, form a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms which are independently selected from the group consisting of oxygen, nitrogen and sulfur while R<sub>1</sub>' is not a number of a ring and is as defined above;

R<sub>4</sub> is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R<sub>5</sub> and R<sub>6</sub> are independently selected from the group consisting of

hydrogen,  
-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and  
-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub>)-alkyl; and

DEAV2001/0073 US NP

PATENT

R7 is selected from the group consisting of

-(C1-C4)-alkyl,

-OH and

-NH<sub>2</sub>;

a stereoisomeric form of the compound of formula I, a mixture of two or more stereoisomeric forms of the compound of formula I, or a physiologically tolerated salt of the compound of formula I,

provided that at least one of the radicals R1, R2, R3, R1', R2', R3' is not selected from the group consisting of hydrogen, halogen, nitro, -(C1-C4)-alkyl and -O-(C1-C4)-alkyl.

2. (Previously Canceled)

3. (Previously Presented) A compound of claim 1, wherein R1, R3, R1', R3' are not selected from the group consisting of halogen, unsubstituted -(C1-C4)-alkyl and unsubstituted -O-(C1-C4)-alkyl except when there is a 5- or 6-membered ring formed between R1 and R2, or between R2 and R3, or between R1' and R2', or between R2' and R3', then R1, R3, R1', R3' are the same as defined in claim 1.

4. (Original) A compound of claim 1, wherein R1, R3, R1', and R3' are independently selected from the group consisting of hydrogen, chlorine, fluorine, trifluoromethyl, methoxy, methyl, -C(O)-OH, -C(O)-O-CH<sub>3</sub>, -CN, -NH<sub>2</sub>, -NH-C(O)-CH<sub>3</sub>, -NH-SO<sub>2</sub>-CH<sub>3</sub>, -N-(CH<sub>3</sub>)<sub>2</sub>, -SO<sub>2</sub>-NH<sub>2</sub>, -OH, -O-CH<sub>2</sub>-(CHF<sub>2</sub>), -S-CH<sub>3</sub>, -S(O)-CH<sub>3</sub>, -S(O)<sub>2</sub>-CH<sub>3</sub> and bromine; and R2 and R2' are independently selected from the group consisting of hydrogen, chlorine, fluorine, methoxy, methyl, bromine, -C(O)-OH, -C(O)-O-CH<sub>3</sub>, -CN, -NH<sub>2</sub>, -NH-C(O)-CH<sub>3</sub>, -NH-SO<sub>2</sub>-CH<sub>3</sub>, -N-(CH<sub>3</sub>)<sub>2</sub>, -SO<sub>2</sub>-NH<sub>2</sub>, -OH, -O-CH<sub>2</sub>-(CHF<sub>2</sub>), -S-CH<sub>3</sub>, -S(O)-CH<sub>3</sub> and -S(O)<sub>2</sub>-CH<sub>3</sub>; or R1 and R2, R2 and R3, R1' and R2', or R2' and R3', together with the two carbon atoms of ring1 or ring2 to which R1 and R2, R2 and R3, R1' and R2', or R2' and R3', respectively, are attached, form a dioxolane, dihydrofuran or furan ring, and any R1, R2, R3, R1', R2', or R3' that is not a member of said dioxolane, dihydrofuran or furan ring is the same as defined in the first part of this claim.

DEAV2001/0073 US NP

PATENT

5. (Original) A compound of claim 1, wherein R1, R3, R1', and R3' are independently selected from the group consisting of hydrogen, -(C1-C4)-alkyl, in which alkyl is substituted once, twice or three times by halogen, and -O-(C1-C4)-alkyl, in which alkyl is substituted once, twice or three times by halogen, and R2 and R2' are independently selected from the group consisting of hydrogen, halogen, -O-(C1-C4)-alkyl, and -(C1-C4)-alkyl; or

R1 and R2, R2 and R3, R1' and R2', or R2' and R3', together with the two carbon atoms of ring1 or ring2 to which R1 and R2, R2 and R3, R1' and R2', or R2' and R3', respectively, are attached, form a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms which are independently selected from the group consisting of oxygen, nitrogen and sulfur, and any R1, R2, R3, R1', R2', or R3' that is not a member of said a 5- or 6-membered ring is independently selected from the group consisting of hydrogen, halogen, -(C1-C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen, and -O-(C1-C4)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen.

6. (Original) A compound of claim 1, wherein R1, R3, R1', and R3' are independently selected from the group consisting of hydrogen and trifluoromethyl, and R2 and R2' are independently selected from the group consisting of hydrogen, chlorine, fluorine, methoxy and methyl; or


R1 and R2, R2 and R3, R1' and R2', or R2' and R3', together with the two carbon atoms of ring1 or ring2 to which R1 and R2, R2 and R3, R1' and R2', or R2' and R3', respectively, are attached, form a dioxolane, dihydrofuran or furan ring, and any R1, R2, R3, R1', R2', or R3' that is not a member of said dioxolane, dihydrofuran or furan ring is independently selected from the group consisting of hydrogen, chlorine, fluorine, trifluoromethyl, methoxy, and methyl.

7. (Original) A process for preparing the compound of formula I as defined in Claim1, comprising:

reacting a compound of formula II


DEAV2001/0073 US NP

PATENT



(II)

with a compound of formula III




(III)

wherein R1, R2 and R3 have the meanings given in claim 1 and Y is halogen, hydroxyl or -(C<sub>1</sub>-C<sub>4</sub>)-alkoxy or, together with the carbonyl group to which Y is attached, forms an active ester or a mixed anhydride, to afford a compound of formula I defined in claim 1.


8. (Original) A process for preparing the compound of formula I as defined in Claim 1, comprising:

reacting a compound of formula II



(II)

with a compound of formula III




(III)

DEAV2001/0073 US NP

PATENT


wherein R1, R2 and R3 have the meanings given in claim 1 and Y is halogen, hydroxyl or -(C<sub>1</sub>-C<sub>4</sub>)-alkoxy or, together with the carbonyl group to which Y is attached, forms an active ester or a mixed anhydride, to afford an intermediate compound of formula IV



; and

reacting said intermediate compound of formula IV with a compound of formula III to afford a compound of formula I as defined in claim 1.

9. (Original) A pharmaceutical composition which comprises an effective amount of at least one compound of claim 1 together with a pharmaceutically suitable and physiologically tolerated carrier substance.
10. (Canceled)
11. (Previously Presented) A method for therapy of a disease which is a degenerative joint disease or a disease of the connective tissue comprising administering a compound of formula I:



I

wherein

A is a nitrogen atom;

DEAV2001/0073 US NP

PATENT

R1 and R3 are independently selected from the group consisting of

hydrogen,

halogen,

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen,

-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen,

-C(O)-O-R<sub>4</sub>,

-CN,

-N(R<sub>5</sub>)-(R<sub>6</sub>),

-OH,

-S-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-S(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and

-S(O)<sub>2</sub>-R<sub>7</sub>, and

R2 is selected from the group consisting of

hydrogen,

halogen,

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-C(O)-O-R<sub>4</sub>,

-CN,

-N(R<sub>5</sub>)-(R<sub>6</sub>),

-OH,

-S-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-S(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and

-S(O)<sub>2</sub>-R<sub>7</sub>; or R1 and R2, taken together with the two carbon atoms of ring1 to

which R1 and R2 are attached, form a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms which are independently selected from the group consisting of oxygen, nitrogen and sulfur while R3 is as defined above; or R2 and R3, taken together with the two carbon atoms of ring1 to which R2 and R3 are



DEAV2001/0073 US NP

PATENT

attached, form a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms which are independently selected from the group consisting of oxygen, nitrogen and sulfur while R1 is not part of a ring and is as defined above;

R1' and R3' are independently selected from the group consisting of

- hydrogen,
- halogen,
- (C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen,
- O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen,
- C(O)-O-R<sub>4</sub>,
- CN,
- N(R<sub>5</sub>)-(R<sub>6</sub>),
- OH,
- S-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- S(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and
- S(O)<sub>2</sub>-R<sub>7</sub>, and

R2' is selected from the group consisting of

- hydrogen,
- halogen,
- (C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- C(O)-O-R<sub>4</sub>,
- CN,
- N(R<sub>5</sub>)-(R<sub>6</sub>),
- OH,
- S-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- S(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and

DEAV2001/0073 US NP

PATENT

-S(O)<sub>2</sub>-R7; or R1' and R2', taken together with the two carbon atoms of ring2 to which R1' and R2' are attached, form a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms which are independently oxygen, nitrogen and sulfur while R3' is as defined above; or R2' and R3', taken together with the two carbon atoms of ring2 to which R2' and R3' are attached, form a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms which are independently selected from the group consisting of oxygen, nitrogen and sulfur while R1' is not a number of a ring and is as defined above;

R4 is hydrogen or -(C<sub>1</sub>-C<sub>4</sub>)-alkyl;

R5 and R6 are independently selected from the group consisting of

hydrogen,

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-C(O)-(C<sub>1</sub>-C<sub>4</sub>)-alkyl and

-SO<sub>2</sub>-(C<sub>1</sub>-C<sub>4</sub>)-alkyl; and

R7 is selected from the group consisting of

-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

-OH and

-NH<sub>2</sub>;

a stereoisomeric form of the compound of formula I, a mixture of two or more stereoisomeric forms of the compound of formula I, or a physiologically tolerated salt of the compound of formula I,

provided that at least one of the radicals R1, R2, R3, R1', R2', R3' is not selected from the group consisting of hydrogen, halogen, nitro, -(C<sub>1</sub>-C<sub>4</sub>)-alkyl and -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl.

12. (Previously Presented) A method for therapy of a degenerative joint disease comprising administering a compound of formula I as defined in claim 1.
13. (Previously Presented) A method according to claim 12, wherein R1, R3, R1', R3' are not selected from the group consisting of halogen, unsubstituted -(C<sub>1</sub>-C<sub>4</sub>)-alkyl and unsubstituted -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl except when there is a 5- or 6-membered ring formed

DEAV2001/0073 US NP

PATENT

between R1 and R2, or between R2 and R3, or between R1' and R2', or between R2' and R3'.

14. (Previously Presented) A method according to claim 12, wherein R1, R3, R1', and R3' are independently selected from the group consisting of hydrogen, chlorine, fluorine, trifluoromethyl, methoxy, methyl, -C(O)-OH, -C(O)-O-CH<sub>3</sub>, -CN, -NH<sub>2</sub>, -NH-C(O)-CH<sub>3</sub>, -NH-SO<sub>2</sub>-CH<sub>3</sub>, -N-(CH<sub>3</sub>)<sub>2</sub>, -SO<sub>2</sub>-NH<sub>2</sub>, -OH, -O-CH<sub>2</sub>-(CHF<sub>2</sub>), -S-CH<sub>3</sub>, -S(O)-CH<sub>3</sub>, -S(O)<sub>2</sub>-CH<sub>3</sub>, and bromine; and

R2 and R2' are independently selected from the group consisting of hydrogen, chlorine, fluorine, methoxy, methyl, bromine, -C(O)-OH, -C(O)-O-CH<sub>3</sub>, -CN, -NH<sub>2</sub>, -NH-C(O)-CH<sub>3</sub>, -NH-SO<sub>2</sub>-CH<sub>3</sub>, -N-(CH<sub>3</sub>)<sub>2</sub>, -SO<sub>2</sub>-NH<sub>2</sub>, -OH, -O-CH<sub>2</sub>-(CHF<sub>2</sub>), -S-CH<sub>3</sub>, -S(O)-CH<sub>3</sub> and -S(O)<sub>2</sub>-CH<sub>3</sub>; or R1 and R2, R2 and R3, R1' and R2', or R2' and R3', together with the two carbon atoms of ring1 or ring2 to which R1 and R2, R2 and R3, R1' and R2', or R2' and R3', respectively, are attached, form a dioxolane, dihydrofuran or furan ring, and any R1, R2, R3, R1', R2', or R3' that is not a member of said dioxolane, dihydrofuran or furan ring is as previously defined.

15. (Previously Presented) A method according to claim 12, wherein R1, R3, R1', and R3' are independently selected from the group consisting of hydrogen, -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is substituted once, twice or three times by halogen, and -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is substituted once, twice or three times by halogen, and R2 and R2' are independently selected from the group consisting of hydrogen, halogen, -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, and -(C<sub>1</sub>-C<sub>4</sub>)-alkyl; or

R1 and R2, R2 and R3, R1' and R2', or R2' and R3', together with the two carbon atoms of ring1 or ring2 to which R1 and R2, R2 and R3, R1' and R2', or R2' and R3', respectively, are attached, form a 5- or 6-membered ring which is aromatic or saturated and contains zero, one or two heteroatoms which are independently selected from the group consisting of oxygen, nitrogen and sulfur, and any R1, R2, R3, R1', R2', or R3' that is not a member of said a 5- or 6-membered ring is independently selected from the group consisting of hydrogen, halogen, -(C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is unsubstituted or

DEAV2001/0073 US NP

PATENT

substituted once, twice or three times by halogen, and -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, in which alkyl is unsubstituted or substituted once, twice or three times by halogen.

16. (Previously Presented) A method according to claim 12, wherein R<sub>1</sub>, R<sub>3</sub>, R<sub>1</sub>' and R<sub>3</sub>' are independently selected from the group consisting of hydrogen and trifluoromethyl, and R<sub>2</sub> and R<sub>2</sub>' are independently selected from the group consisting of hydrogen, chlorine, fluorine, methoxy and methyl; or  
R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>1</sub>' and R<sub>2</sub>', or R<sub>2</sub>' and R<sub>3</sub>', together with the two carbon atoms of ring1 or ring2 to which R<sub>1</sub> and R<sub>2</sub>, R<sub>2</sub> and R<sub>3</sub>, R<sub>1</sub>' and R<sub>2</sub>', or R<sub>2</sub>' and R<sub>3</sub>', respectively, are attached, form a dioxolane, dihydrofuran or furan ring, and any R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>1</sub>', R<sub>2</sub>', or R<sub>3</sub>' that is not a member of said dioxolane, dihydrofuran or furan ring is independently selected from the group consisting of hydrogen, chlorine, fluorine, trifluoromethyl, methoxy, and methyl.
17. (Previously Canceled)
18. (Canceled)
19. (Previously Presented) A method according to claim 11, wherein said disease is a disease of connective tissue.
20. (Previously Presented) A method according to claim 19, wherein said disease of connective tissue is collagenoses, periodontal diseases or wound healing disturbances.
21. (Previously Canceled)
22. (Previously Canceled)
23. (Currently Amended) A method of treatment for breast cancer ~~by using~~ comprising administering to a patient a compound of formula I as defined in claim 1.